Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | General Counsel | September 21, 2026 | September 21, 2026 |
| TerraVia Holdings, Inc.TVIA · Entity 175855 | General Counsel | March 09, 2017 | March 13, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date September 21, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,995 |
Ending reported balance
After 2026-09-21 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-21 · Exercise / conversion · Acquired 10,000 · Balance 39,995 Row 2 · 2026-09-21 · Sale · Disposed 2,900 · Balance 37,095 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Row 3 · 2026-09-21 · Sale · Disposed 3,832 · Balance 33,263 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. Row 4 · 2026-09-21 · Sale · Disposed 601 · Balance 32,662 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive. Row 5 · 2026-09-21 · Sale · Disposed 2,667 · Balance 29,995 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive. |
| Employee Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2034-07-14 | Direct | 79,996 |
Reported balance
After 2026-09-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-21 · Exercise / conversion · Disposed 10,000 · Balance 79,996 F6: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive.
F6: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
TerraVia Holdings, Inc.
Report date March 09, 2017 · Filed March 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 218,403 |
Reported balance
After 2017-03-09 transaction · row 1
1 source rowRow 1 · 2017-03-09 · Sale · Disposed 25,000 · Balance 218,403 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan in connection with the concurrent vesting of restrictred stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7601 to $0.9045, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan in connection with the concurrent vesting of restrictred stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7601 to $0.9045, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CymaBay Therapeutics, Inc.
Report date March 22, 2024 · Filed March 22, 2024
Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-22 · Disposition to issuer · Disposed 41,824 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-22 · Disposition to issuer · Disposed 28,438 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2030-10-11 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-22 · Disposition to issuer · Disposed 233,176 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-22 · Disposition to issuer · Disposed 22,167 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-22 · Disposition to issuer · Disposed 107,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-22 · Disposition to issuer · Disposed 215,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-22 · Disposition to issuer · Disposed 105,625 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2023 Filed Sep 19, 2023 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $16.87 | $84,328.00 |
DisclosureSEC source: 0001062993-23-018278 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.05, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-018278 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 16:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-016606 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 16:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $11.91 | $59,550.50 |
DisclosureSEC source: 0001062993-23-016606 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.64 to $12.21, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 16:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-016606 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 18:52 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-014924 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 18:52 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $11.81 | $59,050.00 |
DisclosureSEC source: 0001062993-23-014924 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 18:52 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-014924 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 16:51 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-014259 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 16:51 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $10.05 | $50,250.00 |
DisclosureSEC source: 0001062993-23-014259 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 16:51 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-014259 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2023 Filed May 17, 2023 19:11 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-011430 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| May 15, 2023 Filed May 17, 2023 19:11 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $10.37 | $51,831.00 |
DisclosureSEC source: 0001062993-23-011430 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.525, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2023 Filed May 17, 2023 19:11 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-011430 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 16:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001062993-23-001488 · form4.xml · derivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2023. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-22-001705 · form4.xml · derivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 14:48 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 22,167 | $0.00 Strike: $5.78 | $0.00 |
DisclosureSEC source: 0001333277-21-000019 · edgar.xml · derivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,167 Underlying: Common Stock · 22,167 shares Expires 2031-01-25 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on January 1, 2022, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 13:22 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001333277-20-000005 · edgar.xml · derivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2030-10-11 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on October 12, 2021, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:29 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 86,445 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001333277-19-000029 · edgar.xml · derivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,445 Underlying: Common Stock · 86,445 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:11 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001333277-18-000026 · edgar.xml · derivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-23 F2 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:11 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001333277-18-000026 · edgar.xml · derivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on December 4, 2018, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 16:58 UTC | TerraVia Holdings, Inc. TVIA · Entity 175855 | SaleCommon Stock | 25,000 | $0.81 | $20,232.50 |
DisclosureSEC source: 0001555667-17-000007 · edgar.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,403 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan in connection with the concurrent vesting of restrictred stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7601 to $0.9045, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 18:55 UTC | TerraVia Holdings, Inc. TVIA · Entity 175855 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001555667-17-000002 · edgar.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-05 F3 · derivative.exercise_date: The option shall vest as to 1/48 of the underlying shares monthly beginning on February 1, 2017. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 18:55 UTC | TerraVia Holdings, Inc. TVIA · Entity 175855 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001555667-17-000002 · edgar.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,403 F2 · shares: The grant shall vest as to all of the shares on March 5, 2018. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 18:55 UTC | TerraVia Holdings, Inc. TVIA · Entity 175855 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001555667-17-000002 · edgar.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,403 F1 · shares: The grant shall vest as to 1/4 of the shares on March 5, 2018 and thereafter shall vest as to 1/8 of the shares on each of September 10, 2018, March 4, 2019, September 9, 2019, March 2, 2020, September 14, 2020 and March 1, 2021. Read SEC document |
| October 14, 2016 Filed Oct 14, 2016 17:38 UTC | TerraVia Holdings, Inc. TVIA · Entity 175855 | SaleCommon Stock | 10,000 | $2.55 | $25,528.00 |
DisclosureSEC source: 0001555667-16-000092 · edgar.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,403 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.525 to $2.58, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Corrects prior share ownership total that overstated holdings by 125 shares. Read SEC document |
| September 16, 2016 Filed Sep 16, 2016 16:11 UTC | TerraVia Holdings, Inc. TVIA · Entity 175855 | SaleCommon Stock | 3,124 | $2.60 | $8,127.40 |
DisclosureSEC source: 0001555667-16-000091 · edgar.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,528 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was designed to cover tax withholding obligations in connection with the concurrent vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.59 to $2.63, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 19:57 UTC | TerraVia Holdings, Inc. TVIA · Entity 175855 | SaleCommon Stock | 1,562 | $2.74 | $4,272.85 |
DisclosureSEC source: 0001555667-16-000090 · edgar.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,652 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was designed to cover tax withholding obligations in connection with the concurrent vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.69 to $2.77, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 2,207 shares acquired under the TerraVia Holdings, Inc. Employee Stock Purchase Plan on August 15, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.